1. Home
  2. MDCX vs GDTC Comparison

MDCX vs GDTC Comparison

Compare MDCX & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDCX
  • GDTC
  • Stock Information
  • Founded
  • MDCX 2008
  • GDTC 2018
  • Country
  • MDCX Canada
  • GDTC Singapore
  • Employees
  • MDCX N/A
  • GDTC N/A
  • Industry
  • MDCX
  • GDTC Biotechnology: Pharmaceutical Preparations
  • Sector
  • MDCX
  • GDTC Health Care
  • Exchange
  • MDCX Nasdaq
  • GDTC Nasdaq
  • Market Cap
  • MDCX 33.8M
  • GDTC 29.4M
  • IPO Year
  • MDCX N/A
  • GDTC 2023
  • Fundamental
  • Price
  • MDCX $2.83
  • GDTC $2.77
  • Analyst Decision
  • MDCX Strong Buy
  • GDTC Buy
  • Analyst Count
  • MDCX 1
  • GDTC 1
  • Target Price
  • MDCX $10.00
  • GDTC $5.00
  • AVG Volume (30 Days)
  • MDCX 9.2K
  • GDTC 33.6K
  • Earning Date
  • MDCX 01-01-0001
  • GDTC 01-01-0001
  • Dividend Yield
  • MDCX N/A
  • GDTC N/A
  • EPS Growth
  • MDCX N/A
  • GDTC N/A
  • EPS
  • MDCX N/A
  • GDTC N/A
  • Revenue
  • MDCX N/A
  • GDTC $330,254.00
  • Revenue This Year
  • MDCX N/A
  • GDTC $14.71
  • Revenue Next Year
  • MDCX N/A
  • GDTC N/A
  • P/E Ratio
  • MDCX N/A
  • GDTC N/A
  • Revenue Growth
  • MDCX N/A
  • GDTC N/A
  • 52 Week Low
  • MDCX $1.80
  • GDTC $1.20
  • 52 Week High
  • MDCX $3.23
  • GDTC $4.05
  • Technical
  • Relative Strength Index (RSI)
  • MDCX N/A
  • GDTC 55.89
  • Support Level
  • MDCX N/A
  • GDTC $2.35
  • Resistance Level
  • MDCX N/A
  • GDTC $2.94
  • Average True Range (ATR)
  • MDCX 0.00
  • GDTC 0.24
  • MACD
  • MDCX 0.00
  • GDTC 0.04
  • Stochastic Oscillator
  • MDCX 0.00
  • GDTC 84.63

About MDCX Medicus Pharma Ltd. Common Stock

Medicus Pharma Ltd is a clinical-stage, multi-strategy holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA approved clinical trials.

About GDTC CytoMed Therapeutics Limited

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

Share on Social Networks: